Intellia Therapeutics, Inc. (NTLA) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Intellia Therapeutics, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Intellia Therapeutics, Inc.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
-18.42%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Turned Positive
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Intellia Therapeutics, Inc. actually do?
Answer:
Intellia Therapeutics is a biopharmaceutical company focused on developing potentially curative treatments for severe diseases using CRISPR gene editing technology. The company's lead product candidates, lonvoguran ziclumeran (lonvo-z) for hereditary angioedema and nexiguran ziclumeran (nex-z) for transthyretin amyloidosis, are the first in vivo genome editing candidates to reach Phase 3 development. These systemically administered therapies are designed for a single intravenous infusion. Intellia is preparing for the U.S. commercial launch of lonvo-z in the first half of 2027 and is advancing its pipeline through internal research and strategic collaborations, notably with Regeneron Pharmaceuticals.
Question:
What are Intellia Therapeutics, Inc.'s revenue drivers?
Answer:
Revenue is primarily derived from collaboration agreements, including upfront payments, milestone payments, research funding, and royalties on licensed products.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required